This Article  • Full text  • PDF  • Incomplete Financial Disclosure  • Correction  • CME Course for This Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

A Meta-analysis

JAMA. 2008;299(19):(doi:10.1001/jama.299.19.jrv80007).

Context  Hemoglobin-based blood substitutes (HBBSs) are infusible oxygen-carrying liquids that have long shelf lives, have no need for refrigeration or cross-matching, and are ideal for treating hemorrhagic shock in remote settings. Some trials of HBBSs during the last decade have reported increased risks without clinical benefit.

Objective  To assess the safety of HBBSs in surgical, stroke, and trauma patients.

Data Sources  PubMed, EMBASE, and Cochrane Library searches for articles using hemoglobin and blood substitutes from 1980 through March 25, 2008; reviews of Food and Drug Administration (FDA) advisory committee meeting materials; and Internet searches for company press releases.

Study Selection  Randomized controlled trials including patients aged 19 years and older receiving HBBSs therapeutically. The database searches yielded 70 trials of which 13 met these criteria; in addition, data from 2 other trials were reported in 2 press releases, and additional data were included in 1 relevant FDA review.

Data Extraction  Data on death and myocardial infarction (MI) as outcome variables.

Results  Sixteen trials involving 5 different products and 3711 patients in varied patient populations were identified. A test for heterogeneity of the results of these trials was not significant for either mortality or MI (for both, I² = 0%, P  .60), and data were combined using a fixed-effects model. Overall, there was a statistically significant increase in the risk of death (164 deaths in the HBBS-treated groups and 123 deaths in the control groups; relative risk [RR], 1.30; 95% confidence interval [CI], 1.05-1.61) and risk of MI (59 MIs in the HBBS-treated groups and 16 MIs in the control groups; RR, 2.71; 95% CI, 1.67-4.40) with these HBBSs. Subgroup analysis of these trials indicated the increased risk was not restricted to a particular HBBS or clinical indication.

Conclusion  Based on the available data, use of HBBSs is associated with a significantly increased risk of death and MI.

Author Affiliations: Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, Maryland (Drs Natanson and Banks and Mr Kern); and Health Research Group, Public Citizen, Washington, DC (Drs Lurie and Wolfe).
Deceased.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTERS

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Lewis J. Levien, Richard E. Hodgson, and Michael F. M. James
JAMA. 2008;300(11):1295.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Peter E. Keipert, Christina Olofsson, and Robert M. Winslow
JAMA. 2008;300(11):1295-1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Roger J. Lewis and Norman Fost
JAMA. 2008;300(11):1296.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Aryeh Shander, Mazyar Javidroozi, and Gary Thompson
JAMA. 2008;300(11):1296-1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Angela Sauaia, Ernest E. Moore, and Anirban Banerjee
JAMA. 2008;300(11):1297.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Babak Sarani and Vicente Gracias
JAMA. 2008;300(11):1297-1298.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Charles Natanson, Peter Lurie, and Sidney M. Wolfe
JAMA. 2008;300(11):1298-1299.
EXTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death—Reply
Dean Fergusson and Lauralyn McIntyre
JAMA. 2008;300(11):1299.
EXTRACT | FULL TEXT  

Incomplete Financial Disclosure in a Study of Cell-Free Hemoglobin-Based Blood Substitutes and Risks of Myocardial Infarction and Death
Charles Natanson
JAMA. 2008;300(11):1300.
EXTRACT | FULL TEXT  

RELATED ARTICLE

The Future of Clinical Trials Evaluating Blood Substitutes
Dean A. Fergusson and Lauralyn McIntyre
JAMA. 2008;299(19):2324-2326.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells
Kaufman
Blood 2009;114:3513-3523.
ABSTRACT | FULL TEXT  

Administration of bovine polymerized haemoglobin before and during coronary occlusion reduces infarct size in rabbits
Rempf et al.
Br J Anaesth 2009;103:496-504.
ABSTRACT | FULL TEXT  

Do approved blood substitutes reduce myocardial infarction size: is this the critical question?
Jahr
Br J Anaesth 2009;103:470-471.
FULL TEXT  

Peculiar flow patterns of RBCs suspended in viscous fluids and perfused through a narrow tube (25 {micro}m)
Sakai et al.
Am. J. Physiol. Heart Circ. Physiol. 2009;297:H583-H589.
ABSTRACT | FULL TEXT  

Hemoglobin research and the origins of molecular medicine
Schechter
Blood 2008;112:3927-3938.
ABSTRACT | FULL TEXT  

Tyrosine Residues as Redox Cofactors in Human Hemoglobin: IMPLICATIONS FOR ENGINEERING NONTOXIC BLOOD SUBSTITUTES
Reeder et al.
J. Biol. Chem. 2008;283:30780-30787.
ABSTRACT | FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Levien et al.
JAMA 2008;300:1295-1295.
FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Lewis and Fost
JAMA 2008;300:1296-1296.
FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Sauaia et al.
JAMA 2008;300:1297-1297.
FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Keipert et al.
JAMA 2008;300:1295-1296.
FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Shander et al.
JAMA 2008;300:1296-1297.
FULL TEXT  

Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death
Sarani and Gracias
JAMA 2008;300:1297-1298.
FULL TEXT  

Incomplete Financial Disclosure in a Study of Cell-Free Hemoglobin-Based Blood Substitutes and Risks of Myocardial Infarction and Death
Natanson
JAMA 2008;300:1300-1300.
FULL TEXT  

The Future of Clinical Trials Evaluating Blood Substitutes
Fergusson and McIntyre
JAMA 2008;299:2324-2326.
FULL TEXT